Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 3,497 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly

NCT02082418
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Alpha-lactalbumin, Whey, Casein
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
55 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04619797
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 5:55 PM EDT
Terminated Phase 4 Interventional Results available

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

NCT01531803
View directory record Official record
Conditions
Hypovolemia
Interventions
Kedbumin 25%, Normal Saline Solution
Drug
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
Up to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Louisville, Kentucky • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 24, 2026, 5:55 PM EDT
Recruiting Phase 1 Interventional

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

NCT07075120
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

NCT04376762
View directory record Official record
Conditions
Pediatric HD, Bleeding
Interventions
Fibrinogen, Cryoprecipitate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
Up to 24 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

DailyDose Smart Snack Study for T1D on MDI

NCT05967260
View directory record Official record
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
DailyDose Smart Snack app, Dexcom G6 CGM
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 3 Interventional

Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer

NCT00028574
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
170
States / cities
Mobile, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 24, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Botox in Obstructed Defecation Syndrome

NCT02160288
View directory record Official record
Conditions
Obstructed Defecation Syndrome (ODS)
Interventions
Botulinum Toxin-A, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 24, 2026, 5:55 PM EDT
Terminated Phase 3 Interventional

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

NCT03520686
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 24, 2026, 5:55 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Photodynamic Therapy for Cutibacterium Acnes (C. Acnes) Decolonization of the Shoulder Dermis

NCT04636242
View directory record Official record
Conditions
C. Acnes, Phototherapy, Postoperative Infection, Arthroscopic Rotator Cuff Repair, Shoulder Surgery
Interventions
Skin Biopsy, 5 Aminolevulinic Acid + Phototherapy
Procedure · Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

NCT00653822
View directory record Official record
Conditions
Pharmacokinetics of Alefacept
Interventions
alefacept, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
20 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 24, 2026, 5:55 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 24, 2026, 5:55 PM EDT
Withdrawn Not applicable Interventional

Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity

NCT02977039
View directory record Official record
Conditions
Type 2 Diabetes Mellitus in Obese
Interventions
NDPR diet, USDA healthy eating diet
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Beneficial Effects of Healthy Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People

NCT01781286
View directory record Official record
Conditions
Obesity
Interventions
High Protein, Low Protein
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
13 Years to 19 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 24, 2026, 5:55 PM EDT
Withdrawn No phase listed Observational

Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients

NCT01795170
View directory record Official record
Conditions
Pyridoxine Dependant Epilepsy
Interventions
Lysine Restricted Diet, Pyridoxine
Dietary Supplement · Drug
Lead sponsor
University of British Columbia
Other
Eligibility
3 Months to 3 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 24, 2026, 5:55 PM EDT
Not listed Not applicable Interventional

Dietary Sodium-Restriction (DIS) and Renal Meals (RM) for Hemodialysis (HD)(DISaRM-HD)

NCT04991441
View directory record Official record
Conditions
Kidney Failure, Chronic, Dietary Modification
Interventions
Controlled Dietary Sodium Restriction, Control Diet & Controlled Dietary Sodium Restriction
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 24, 2026, 5:55 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Spinal Cord Associative Plasticity Study

NCT05163639
View directory record Official record
Conditions
Cervical Spinal Cord Injury, Tetraplegia/Tetraparesis, Cervical Myelopathy
Interventions
Non-invasive pairing of cortical and spinal stimulation, Intraoperative pairing of cortical and spinal stimulation, Non-invasive repeated pairing of cortical and spinal stimulation (SCAP), Intraoperative repeated pairing of cortical and spinal stimulation (SCAP), Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

NCT01695239
View directory record Official record
Conditions
Psoriasis, Arthritic
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 24, 2026, 5:55 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Machine Learning Sepsis Alert Notification Using Clinical Data

NCT04005001
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
HindSight, InSight
Other
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
37,986 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Springfield, Massachusetts • Camden, New Jersey • Cape May, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder

NCT01934972
View directory record Official record
Conditions
Bipolar Disorder
Interventions
CR + DCS (D-cycloserine), CR + placebo
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 24, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Abatacept Conversion in Kidney Transplantation

NCT04955366
View directory record Official record
Conditions
Renal Transplant Recipient
Interventions
Belatacept, Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 24, 2026, 5:55 PM EDT